https://www.selleckchem.com/pr....oducts/brigatinib-ap
99, 95% CI 0.55-1.79, low certainty of evidence) by children and adolescents with ASD. Parents and clinicians did not raise significant issues concerning acceptability. We did not find studies reporting evidence of reduced equity for antipsychotics in disadvantaged subgroups of children and adolescents with ASD. Workloads, cost barriers, and inadequate monitoring of metabolic adverse events were indirect evidence of concerns for feasibility. Antipsychotics in children and adolescents with ASD were likely acceptable and possib
Like
Comment
Share
